Susan Sobolov


Dr. Sobolov joined Caelum as Chief Operating Officer in March 2019 and is now part of AstraZeneca after acquisition in October 2021.  As COO, she led CMC, Quality, regulatory and translational sciences. Prior to Caelum, Dr. Sobolov was Vice President of Strategy, Portfolio and Program Management at Fortress Biotech where she led building out a number of subsidiary companies, including Mustang Bio (CAR-T and cell therapy), Caelum (antibody for AL amyloidosis), Avetis (complement gene therapy), Tamid (gene therapy MPS1) along with advising Oncogenuity (PNAs).  Dr. Sobolov was a Research and Development Team Leader at Alexion where she led the late stage development of Strensiq™, and led Alexion’s mRNA collaboration with Moderna. Before joining Alexion, Dr. Sobolov was Global Head of the PMO at Novartis Institute of Biomedical Research.  Earlier in her career she was Vice President and Program Executive for Incivek™ at Vertex.  Dr. Sobolov began her industry career at Pfizer as a medicinal chemist in oncology providing development support for Tarceva™ and rose through positions of increasing responsibility to Senior Director and Global Development Team Leader in Neuroscience. She holds a PhD., MS, and M.Phil degree in organic chemistry from Yale University. Dr. Sobolov completed an American Cancer Society post-doctoral fellowship at Harvard Medical School in enzymology and molecular biology.

Contact Information